ORKA · Oruka Therapeutics, Inc.

Current Thesis

Oruka Therapeutics’ extended-dosing psoriasis thesis turns on whether September’s EVERLAST-A results preserve the reported skin-clearance response; a daily close below $82 invalidates its price structure. The clinical test is Week 28 durability, guided to the end of September in the company’s August 10 update. The research case requires the reported complete-clearance rate to hold at least the Week 16 benchmark on a comparable patient population and analysis method. August 10 corporate update

The development since the September 5 note is a September 9 announcement of attendance at the Morgan Stanley healthcare conference on September 14–16, 2026. That announcement contains no clinical result or exact readout date. September 9 announcement

As an inference, the narrative is maturing — the clinical timetable has been public since August 10, while the September 11 reference close remains 18.3% below the reported 52-week high. Conference attendance supplies another communication venue, but the announcement does not resolve durability.

Bullish and bearish views on Oruka Therapeutics, Inc.

The model's bull view on Oruka Therapeutics, Inc. (ORKA), in brief: Complete clearance has been measured. On April 27, 2026, Oruka reported that 40 of 63 treated participants, or 63.5%, achieved complete clearance on the Psoriasis Area and Severity Index (PASI 100) at Week 16. That establishes the comparison for the next observation; it does not… The bear view: Extended durability remains unproven. The April 27 result covers Week 16 in 63 treated participants. That sample and observation period cannot support a conclusion about annual disease control or superiority to another treatment. April 27 results Issuance capacity remains… Both cases follow in full.

Bull Case

• Complete clearance has been measured. On April 27, 2026, Oruka reported that 40 of 63 treated participants, or 63.5%, achieved complete clearance on the Psoriasis Area and Severity Index (PASI 100) at Week 16. That establishes the comparison for the next observation; it does not establish annual efficacy. April 27 results
• Funding supports continued development. Oruka reported $1.1 billion in cash, cash equivalents and marketable securities at June 30, 2026. Management’s August 10 statement projected funding through an anticipated ORKA-001 biologics license application; this is company guidance, not a guaranteed runway. August 10 corporate update
• Independent replication is approaching. The August 10 update reported EVERLAST-B fully enrolled with 187 participants and Week 16 results expected in the fourth quarter of 2026. Those results remain necessary evidence beyond the smaller EVERLAST-A cohort. August 10 corporate update

Bear Case

• Extended durability remains unproven. The April 27 result covers Week 16 in 63 treated participants. That sample and observation period cannot support a conclusion about annual disease control or superiority to another treatment. April 27 results
• Issuance capacity remains material. The August 27, 2026 prospectus supplement disclosed an at-the-market equity program of up to $500 million. The filing establishes potential supply; it does not establish that shares were issued or that issuance caused the subsequent price weakness.
• Analyst support has not resolved weakness. Benzinga reported H.C. Wainwright maintaining its $120 analyst price target on September 3, 2026. The September 11 market close was $92.38; the target is a third-party valuation opinion, not evidence that clinical durability has been demonstrated.

Setup & Price Structure

The supplied adjusted daily-bar series records a September 11, 2026 close of $92.38, a three-month price increase of 32.2%, and a 14-period relative strength index (RSI) of 21.1. The same snapshot places the shares 18.3% below their $113.08 52-week high. These measurements show that the earlier advance and the recent weakness coexist; they do not establish a reversal.

The close remains below the $97.78 structural marker identified in the September 5 public note. A weekly close above $97.78 would overturn the narrow finding that this marker remains unrecovered. The $82 lower boundary retained in that public framework remains the thesis-break threshold, rather than a newly calculated support level.

Current exchange-verified short interest, a moving-average series and a dated retail-coverage count are missing. Crowding therefore cannot be classified from this record. The August 27 issuance authorization and the approaching September clinical window are observable supply and event exposures; neither measures investor positioning.

Catalyst Calendar (next 30 days)

• ~2026-09-30, estimated — EVERLAST-A Week 28 results. August 10 guidance specifies the end of the third quarter, not September 30 as an appointment. The release tests maintenance of response toward six months; that calendar date represents the guidance deadline. Corporate update

Elapsed catalysts

• 2026-09-14 through 2026-09-16 — Healthcare conference. Oruka’s September 9 announcement confirms attendance at the Morgan Stanley Global Healthcare Conference. It names no presentation time or accompanying clinical disclosure. Company announcement (passed 4d ago)

What Would Change Our Mind

Loss of the July support framework would end the price-supported case: a daily close below $82 is the observable invalidation. This retains the September 5 published threshold without claiming that a technical boundary predicts a clinical outcome.

The clinical case would fail if the forthcoming Week 28 PASI 100 rate falls below the April 27 benchmark of 63.5% using a comparable population and analysis method. This is a research criterion, not a company-specified statistical endpoint. September 30, 2026 passing without the guided results would separately invalidate the on-time catalyst assumption; an incomparable analysis would leave durability unresolved rather than establish success.

Correlation Notes

The September 13, 2026 coverage context assigns Oruka to no active theme cluster. This dossier therefore treats the September readout as a single-company clinical event. No matched return series is supplied, so a numerical correlation with biotechnology equities or other immunology developers cannot be stated. The theme tags describe subject matter, not measured co-movement.